Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 19/7/2019
SIETES contiene 92793 citas

 
 
 1 a 20 de 1716 siguiente >>
Presentar resultados
Seleccionar todas
3.Enlace a cita original Cita con resumen
Sultana J, Moretti U, Addis A, Caduff P, Capuano A, Kant A, Laporte JR, Lindquist M, Raine J, Sartori D, Trifirò G, Tuccori M, Venegoni M, van Puijenbroek E, Leone R. Workshop on the Italian pharmacovigilance system in the international context: critical issues and perspectives. Drug Saf 2019;42:mayo. [Ref.ID 103115]
4.Enlace a cita originalTiene citas relacionadas Cita con resumen
Dayoub EJ, Seigerman M, Tuteja S, Kobayashi T, Kolansky DM, Giri J, Groeneveld PW. Trends in platelet adenosine diphosphate P2Y12 receptor inhibitor use and adherence among antiplatelet-naive patients after percutaneous coronary intervention, 2008-2016. JAMA Intern Med 2018;178:julio. [Ref.ID 102882]
5. Cita con resumen
Anónimo. Muscle drug determined too expensive for UK’s NHS. DIA Daily 2018:14 de agosto. [Ref.ID 102787]
6. Cita con resumen
Mole B. “Is curing patients a sustainable business model?” Goldman Sachs analysts ask. Ars Technica 2018:12 de abril. [Ref.ID 102511]
8. Cita con resumen
Hamel MB. Speed, safety, and industry funding — From PDUFA I to PDUFA VI. N Engl J Med 2017;377:2278-86. [Ref.ID 102166]
9.Tiene citas relacionadas Cita con resumen
Godlee F, Abbasi K, Bloom T. BMJ declares its revenues from industry. BMJ 2017;359:j4930. [Ref.ID 102109]
10.Tiene citas relacionadas Cita con resumen
Liu JJ, Bell CM, Matelski JJ, Detsky AS, Cram P. Payments by US pharmaceutical and medical device manufacturers to US medical journal editors: retrospective observational study. BMJ 2017;359:j4619. [Ref.ID 102108]
13. Cita con resumen
Iacobucci G. NHS to stop funding homeopathy and some drugs in targeted savings drive. BMJ 2017;358:j3560. [Ref.ID 102013]
14. Cita con resumen
Anónimo. WHO’s travel expenses exceed what it spends on some diseases. DIA Daily 2017:1. [Ref.ID 101587]
15.Tiene citas relacionadas Cita con resumen
Spelsberg A , Prugger C , Doshi P , Ostrowski K , Witte T , Hüsgen D , Keil U , for the Working Group on Health and Working Group on Freedom of Information Transparency International Deutschland eV. Contribution of industry funded post-marketing studies to drug safety: survey of notifications submitted to regulatory agencies. BMJ 2017;356:j337. [Ref.ID 101390]
16. Cita con resumen
17. Cita con resumen
19. Cita con resumen
20. Cita con resumen
Kesselheim AS, Avorn J, Sarpatwari A. The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA 2016;316:858-71. [Ref.ID 100589]
Seleccionar todas
 
 1 a 20 de 1716 siguiente >>